Managing Your Due Diligence Process Throughout the Life Cycle of a Life Sciences Company

04 December 2007 Past Event

Ensuring top value of a product throughout the lifecycle process involves managing issues related to evaluating a potential product; Identifying the best people for a project, recognizing key value factors of a product, and managing the size, flow and duration of a project. This panel will specifically address:

  • How does your evaluation of a project differ in the big Pharma setting vs. a more entrepreneurial setting?
  • What factors do you consider in determining whether their will be life after the patent on the active
  • How have considerations changed in doing research (basic and developmental) in the last 10 years?
  • What are some sources for evaluating the likelihood of success of a project?

Panelists include: Kim Graham, Former Director, Cambridge Antibody Technology Inc.; Ed LeFevre, Partner, Foley; Roberto Rosenkranz, Ph.D., Chairman and CEO, ROXRO PHARMA; and L. James Strand, M.D., General Partner, Managing Director, Institutional Venture Partners (IVP).


Hatch Comments on DNC-Related Construction Projects in Milwaukee
14 June 2019
Milwaukee Business Journal
Bernard Quoted on Debt-Relief Settlement with ITT Tech Lender
14 June 2019
Wall Street Journal
Dodd and Daughter Profiled in Wisconsin Golf
13 June 2019
Wisconsin Golf
Brinckerhoff Comments on SCOTUS Ruling in Patent Case
11 June 2019
Intellectual Property Magazine
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
2019 NDI Executive Exchange
14-15 November 2019
Chicago, IL
Association for Corporate Counsel Annual Meeting 2019
27-30 October 2019
Phoenix, AZ
Foley's Government Contracts Annual Update
16 October 2019
Liviona, MI